Robert Goertsches
About Robert Goertsches
Robert Goertsches serves as the ALS Area Lead at Amylyx Pharmaceuticals in Göttingen, Germany. He has extensive experience in the pharmaceutical industry, having held various roles in medical scientific liaison and management across multiple companies.
Current Role at Amylyx Pharmaceuticals
Robert Goertsches serves as the ALS Area Lead at Amylyx Pharmaceuticals, a position he has held since 2022. He is based in Göttingen, Niedersachsen, Deutschland. In this role, he focuses on advancing the company's initiatives related to amyotrophic lateral sclerosis (ALS), contributing to the development and implementation of strategies aimed at improving patient outcomes.
Previous Experience at Biogen
Prior to his current role, Robert Goertsches worked at Biogen from 2018 to 2022. He held two positions: Senior Medical Science Liaison (MSL) for Multiple Sclerosis from 2018 to 2021 and Senior Medical Liaison Manager (MLM) for Alzheimer’s Disease from 2021 to 2022. His work involved engaging with healthcare professionals and supporting clinical initiatives related to these neurological conditions.
Experience at Teva Pharmaceuticals
Robert Goertsches has significant experience at Teva Pharmaceuticals, where he worked in various roles from 2013 to 2017. He served as Medical Scientific Liaison Manager for CNS from 2013 to 2015 and then as Head of Medical Scientific Liaison for CNS from 2015 to 2017. His responsibilities included facilitating communication between the company and the medical community regarding central nervous system therapies.
Background in Neuroscience at Novartis
Robert Goertsches began his career in the pharmaceutical industry at Novartis, where he worked as Medical Scientific Liaison Manager in Neuroscience from 2011 to 2013. In this role, he contributed to the dissemination of scientific information and supported the development of neuroscience-related products.
Academic Background
Robert Goertsches studied at Georg-August Universität Göttingen from 1996 to 1999 and at Universität Osnabrück from 1992 to 1995. His educational background laid the foundation for his expertise in medical science and research, particularly in the field of neuroscience.